louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03777423: Comparison Between Injection Molded PEEK Framework and Cobalt Chromium Framework Removable Partial Dentures Regarding Biting Force
Official title: Evaluation of Biting Force of Removable Partial Denture Made of Injection Molded PEEK Framework Versus Cobalt Chromium Framework in Mandibular Kennedy Class I Edentulous Cases
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Mandibular Prosthesis User
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-12-17
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is aiming to evaluate the biting force of polyetheretherketone (PEEK) framework partial dentures compared to that of cobalt-chromium ones in mandibular Kennedy class I edentulous cases hoping that polyetheretherketone (PEEK) framework removable partial dentures can improve the patient masticatory efficiency .


Eligibility criteria: Inclusion Criteria:

-Kennedy class 1 partially edentulous subjects indicated for framework partial denture

Exclusion Criteria:

* Uncooperative patients
* Bad oral hygiene patients

Primary outcomes:
measure: Biting force
timeFrame: Change in baseline biting force from time of insertion, insertion after 1 month and after 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of oral and dental medincine Cairo university
Study officials:
References:
citation: Al-Jammali ZM. Clinical Evaluation of Maximum Bite Force in Patient with Heat Cure acrylic and Flexible Partial Dentures. Medical Journal of Babylon. 2017;14(3):509-17.
Clinical trial NCT00635323: Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma
Official title: A Phase 2 Study of the Efficacy and Safety of Irinotecan (Campto®) in Combination With Capecitabine (Xeloda®) as First-Line Chemotherapy in Asian Subjects With Inoperable Hepatocellular Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Carcinoma, Hepatocellular
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2008-03-13
Enrollment: 73
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the safety and efficacy of irinotecan and capecitabine in Asian subjects with inoperable hepatocellular carcinoma.


Eligibility criteria: Inclusion Criteria:

* Asian subjects with histologically or cytologically confirmed hepatocellular carcinoma
* Inoperable disease (unable to completely remove surgically, presence of extra-hepatic disease, main portal vein or hepatic vein involvement)
* Eastern Cooperative Oncology Group performance status of ?2

Exclusion Criteria:

* Decompensated cirrhosis or stage C (Index\>10) according to the Child-Pugh Classification
* Current history of chronic diarrhoea
* Reproductive potential not using adequate contraceptive measures

Primary outcomes:
measure: Overall response rate
timeFrame: Week 6
Secondary outcomes:
measure: Time to progression
timeFrame: Weeks 6, 12, 18, 24, 36, and 1 year
measure: Duration of overall response
timeFrame: Weeks 6, 12, 18, 24, 36, and 1 year
measure: Overall tumour growth control rate
timeFrame: Weeks 6, 12, 18, 24, 36, and 1 year
measure: Overall survival
timeFrame: Weeks 6, 12, 18, 24, 36, and 1 year
measure: Adverse events
timeFrame: Weeks 6, 12, 18, 24, 36, and 1 year
measure: Physical exam
timeFrame: Weeks 6, 12, 18, 24, 36, and 1 year
measure: Laboratory tests
timeFrame: Weeks 6, 12, 18, 24, 36, and 1 year
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Pfizer Investigational Site
city: Hong Kong SAR
country: Hong Kong
facility: Pfizer Investigational Site
city: Seoul
country: Korea, Republic of
facility: Pfizer Investigational Site
city: Seoul
country: Korea, Republic of
facility: Pfizer Investigational Site
city: Seoul
country: Korea, Republic of
facility: Pfizer Investigational Site
city: Seoul
country: Korea, Republic of
facility: Pfizer Investigational Site
city: Keelung
country: Taiwan
facility: Pfizer Investigational Site
city: Taipei
country: Taiwan
facility: Pfizer Investigational Site
city: Taipei
country: Taiwan
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT06692023: Impact of HI-NPPV Vs LI-NPPV on Tolerance Among AECOPD Patients
Official title: Impact of High-Intensity-NIV Vs Low-intensity-NIV on Subjective Tolerance Amomg Patients with AECOPD : a Randomised Cross-over Pilot Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Lead sponsor: Beijing Chao Yang Hospital
Sponsor class: OTHER
First posted: 2024-11-18
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To determine whether high-intensity NPPV, compared with low-intensity NPPV, could have an effect on the subjective tolerance in patients with an AECOPD and hypercapnia.

Detailed description: To evaluate the subjective tolerance of high-intensity NPPV and low-intensity NPPV patients in a conscious state by two questionnaire surveys; To assess tolerance of high-intensity NPPV and low-intensity NPPV patients patient in sleeping status by PSG monitoring.

Eligibility criteria: Inclusion Criteria:

* AECOPD confirmed by the 2019 criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD);
* Arterial pH \<7.35 and PaCO2 \>45 mmHg at screening entry;
* PaCO2 \>45 mmHg after a 6-hour trial of low-intensity NPPV.

Exclusion Criteria:

* Age \<18 years
* Excessive respiratory secretions with weak cough
* Upper airway obstruction
* Recent oral, facial, or cranial trauma or surgery
* Recent gastric or esophageal surgery
* Presence of restrictive ventilatory dysfunction (eg, consolidation or removal of at least one pulmonary lobe, massive pleural effusion, chest wall deformity, continuous strapping with thoracic or abdominal bandage, or severe abdominal distension)
* Active upper gastrointestinal bleeding
* Cardiac or respiratory arrest
* Arterial oxygen tension/fraction of inspired oxygen (PaO2/FiO2) \<100 mmHg
* Pneumothorax
* Obvious emphysematous bullae confirmed by chest CT scan
* Ventricular arrhythmia or myocardial ischemia
* Severe hemodynamic instability (mean arterial pressure \<65 mmHg)
* Severe metabolic acidosis (pH \<7.20 and bicarbonate \<22 mmol/L)
* Refusal to receive NPPV or give informed consent
* Prior endotracheal intubation or tracheostomy during the current hospitalization
* A do-not-intubate order

Primary outcomes:
measure: NPPV subjective tolerance
timeFrame: From randomization to 2 days after randomization
Secondary outcomes:
measure: Effects of NPPV on sleep quality
timeFrame: From randomization to 2 days after randomization
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Chao Yang Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT01212523: Effects of Propofol and Isoflurane on Pulmonary Vascular Resistance
Official title: Randomised Cross-over Pilot Study to Determine the Effects of Isoflurane and Propofol on Pulmonary Vascular Resistance in Children With Pulmonary Hypertension.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension, Pulmonary
Keywords: propofol
isoflurane
pulmonary hypertension
congenital heart disease
Lead sponsor: University Hospitals Bristol and Weston NHS Foundation Trust
Sponsor class: OTHER
First posted: 2010-09-30
Enrollment: 10
Sex: ALL
Minimum age (years): 3
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: The investigators hypothesize that there is no difference between the effects of isoflurane and propofol anaesthesia on pulmonary vascular resistance (PVR).


Eligibility criteria: Inclusion Criteria:

* All children between 3 months and 16 years of age with pulmonary arterial hypertension undergoing a PVR study.

Exclusion Criteria:

* Children with a known adverse reaction to one of the study drugs eg malignant hyperpyrexia or a disorder of fatty acid oxidation.

Primary outcomes:
measure: The primary endpoint is the percentage change in PVR under isoflurane anaesthesia compared with propofol anaesthesia.
timeFrame: 2 hours
Secondary outcomes:
measure: The secondary endpoints are the percentage change in mean pulomanry artery pressure (PAP), systemic vascular resistance (SVR) and mean arterial pressure (MAP).
timeFrame: 2 hours
Other outcomes:
Locations:
city: Bristol
country: United Kingdom
facility: UH bristol NHS Trust
Study officials:
References:
Clinical trial NCT00610350: Levosimendan and Myocardial Protection
Official title: Levosimendan Pre-Treatment in Patients Undergoing Coronary Artery Bypass Graft Surgery: a Double-Blind, Single Center, Prospective, Randomized, Placebo-Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Myocardial Protection
Keywords: Levosimendan
pre-conditioning
cardiac surgery
myocardial function
contractility
heart
ischaemia
Lead sponsor: University of Roma La Sapienza
Sponsor class: OTHER
Collaborators: name: University College London Hospitals
First posted: 2008-02-07
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to investigate whether pharmacological pre-treatment with levosimendan reduces intensive care unit (ICU) length of stay in patients undergoing elective myocardial revascularization under cardiopulmonary bypass.


Eligibility criteria: Inclusion Criteria:

* age ≥18 years
* intention to perform first-time multi-vessel CABG

Exclusion Criteria:

* unstable angina
* valvular disease
* diabetes mellitus treated with sulphonylurea drugs
* renal failure
* severe hepatic disease
* severe chronic obstructive pulmonary disease
* a history of prior CABG surgery
* recent myocardial infarction (MI) within the previous month

Primary outcomes:
measure: Length of ICU stay
timeFrame: two weeks
Secondary outcomes:
measure: Length of hospital stay
timeFrame: 3 weeks
measure: Tracheal intubation time
timeFrame: one week
measure: Inotropic support over the first 7 days
timeFrame: one week
Other outcomes:
Locations:
city: Rome
country: Italy
facility: University of Rome "Sapienza"
Study officials:
affiliation: University of Roma La Sapienza
name: Vincenzo De Santis, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Tritapepe L, De Santis V, Vitale D, Guarracino F, Pellegrini F, Pietropaoli P, Singer M. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth. 2009 Feb;102(2):198-204. doi: 10.1093/bja/aen367.
Clinical trial NCT00050050: Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder
Official title: CBT for Residual ADHD Symptoms in Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Attention Deficit Disorder With Hyperactivity
Keywords: Adult
ADHD
ADD
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2002-11-21
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will determine the effectiveness of cognitive behavioral therapy (CBT) in treating the symptoms of attention deficit hyperactivity disorder (ADHD) in adults who have not responded to drug treatment.

Study hypothesis: CBT is an effective treatment for adult ADHD.

Detailed description: ADHD, previously believed to be a disorder of childhood, affects as many as 5 percent of adults. Adults with ADHD are at high risk for academic and occupational underachievement, relationship difficulties, and reduced quality of life. This study will determine whether CBT is more effective than drug therapy in treating ADHD symptoms in adults who have been resistant to previous drug therapies.

Participants will be randomly assigned to receive 12 to 15 weekly sessions of either CBT or drug therapy which may include new or previously taken drugs. Questionnaires will be used to assess participants' ADHD symptoms at study start and at study completion.

Eligibility criteria: Inclusion Criteria:

* Adult ADHD of at least moderate severity
* On current drug therapy for ADHD

Exclusion Criteria:

* Depression, panic disorder, bipolar disorder, organic mental disorders, psychotic disorders, or pervasive developmental disorders
* Current substance abuse or dependence
* IQ less than 90
* Suicide risk
* History of cognitive behavioral therapy

Primary outcomes:
measure: ADHD symptoms
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Steven A. Safren, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05764850: Mechanisms of Type 1 Diabetes Endophenotypes
Official title: Mechanisms of Type 1 Diabetes Endophenotypes, by Cluster Analysis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Type 1 Diabetes Mellitus
Genetic Predisposition to Disease
Keywords: Type 1 diabetes mellitus
Children
Adolescent
Young adult
Genetic
Transcriptomic
Metabolomic
Lipidomic
Genetic risk score
Lead sponsor: Pediatric Clinical Research Platform
Sponsor class: OTHER
Collaborators: name: University Hospital, Geneva
name: University of Geneva, Switzerland
First posted: 2023-03-13
Enrollment: 150
Sex: ALL
Minimum age (years): 0
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children, adolescents, and young adults followed at the pediatric diabetology unit of the University Hospital of Geneva.

Controls Children, adolescents, and young adults coming for a routine blood sample at University Hospital of Geneva

Brief summary: The goal of this observational study consists of performing cluster analysis to decipher underlying disease mechanisms of type 1 diabetes in children and young adults.

To this end, we will combine clinical, laboratory, genetic, transcriptomic, and metabolomic datasets of an extensively phenotyped cohort of children and young adults with type 1 diabetes. We will also assess the risk for cardiovascular diseases in this most vulnerable diabetes cohort.


Eligibility criteria: Inclusion Criteria (Type 1 Diabetic patients):

* Informed consent as documented by signature
* Patient's age: between 0 and 25 years old.
* Children, adolescents, and young adult patients followed in diabetology.

Exclusion Criteria (Type 1 Diabetic patients):

* No exclusion criteria

Inclusion Criteria (Controls):

* Informed consent as documented by signature
* Patient's age: 25 less than 6 years of age and 25 between 6 and 25 years old.
* Healthy patient

Exclusion Criteria (Controls):

* Patient receiving treatment affecting metabolic control (ex: systemic corticoids, beta blocker, immunotherapy etc.)
* Concomitant disease that may affect the analysis of the results (ex: cancer, active autoimmune disease requiring treatment)

Primary outcomes:
measure: Cluster analysis to decipher underlying mechanisms of type 1 diabetes
timeFrame: blood sampling and analyses
Secondary outcomes:
Other outcomes:
Locations:
city: Geneva
country: Switzerland
facility: University Hospital of Geneva
Study officials:
affiliation: University Hospital of Geneva / University of Geneva
name: Valerie VS Schwitzgebel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00479050: Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm
Official title: Phase 1 Study of Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hepatocellular Carcinoma
Keywords: Hepatocellular carcinoma,treatment
Lead sponsor: Shandong University
Sponsor class: OTHER
First posted: 2007-05-25
Enrollment: 291
Sex: ALL
Minimum age (years): 45
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Combined the chemoembolization and Radiofrequency ablation for the hepatocellular carcinoma greater than 3 cm,the ablation volume of coagulation necrosis can be significantly increased,which may be enable effective treatment of patients with HCC greater than 3 cm.

Detailed description: To assess whether the effectiveness of a combination of transcatheter arterial chemoembolization(TACE) and radiofrequency ablation(RFA) is superior to TACE and RFA alone in treatment of patients with hepatocellular carcinoma(HCC)greater than 3 cm and to analyze the factors affecting the outcomes.

The patients with HCC of 3 or fewer lesions, each 3cm greater in diameter entered this randomized controlled trial. The primary end point was survival, and the secondary end points were tumor response.

Eligibility criteria: Inclusion Criteria:

Eligibility criteria were:

1. Not indicated for resection,
2. Liver function of Child-Pugh class A or B,
3. 3 or fewer lesion, each 3 cm greater and 7.5 cm less in greatest diameter,
4. No portal vein involvement or extrahepatic metastasis,
5. Lesions located at least 5mm away from the hepatic hilum or gall bladder and the common bile duct,
6. Platelet count≥6.0×103/mm3 and the prothrombin activity≥60%, and
7. No previous HCC treatment.

Exclusion Criteria:

Exclusion criteria were:

1. Encephalopathy,
2. Refractory ascites,
3. Active gastrointestinal bleeding,
4. Renal failure.

Primary outcomes:
measure: overall survival
timeFrame: 5 years
Secondary outcomes:
measure: tumor response
timeFrame: 1-6 months
Other outcomes:
Locations:
Study officials:
affiliation: Dept. of Radiology
name: Wang Qi Liang, MD,PhD
role: STUDY_CHAIR
References:
citation: Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL, Yi CH. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA. 2008 Apr 9;299(14):1669-77. doi: 10.1001/jama.299.14.1669.
Clinical trial NCT04772950: Measuring Deep and Superficial Multifidus and the Activation Pattern During Dynamic Task Correlating With Trunk Stability Ability and Functional Performance in Different Ages Asymptomatic and Unspecific Low Back Pain Adult
Official title: Measuring Deep and Superficial Multifidus and the Activation Pattern During Dynamic Task Correlating With Trunk Stability Ability and Functional Performance in Different Ages Asymptomatic and Unspecific Low Back Pain Adult
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Low Back Pain
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2021-02-26
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: patients with non-specific low back pain

Brief summary: The first propose of the study is to understand the contraction of deep and superficial multifidus in patients with non-specific low back pain and the elderly. The second purpose of the study is to understand the relationship between the multifidus and the functional performance in patients with non-specific low back pain and the elderly. The hypothesis is that the patients with non-specific low back pain and the elderly have less ability to contract the deep multifidus then asymptomatic adults and younger adults. Besides, the multifidus is correlated to the functional performance.


Eligibility criteria: Inclusion Criteria:

* age 20-90
* have lumbar region discomfort in the past three months, and the discomfort is more than one day
* have diagnosis of non-specific low back pain

Exclusion Criteria:

* have received surgery of lumbar or lower extremities
* neurological symptom (eg. numbness of lower extremities)
* have no ability to stand and walking independently
* cancer
* systemic disease (eg. ankylosing spondylitis, rheumatoid arthritis, Systemic lupus erythematosus)
* pregnancy

Primary outcomes:
measure: Change of superficial multifidus
timeFrame: 10 minutes
measure: Change of deep multifidus
timeFrame: 10 minutes
measure: Disability index
timeFrame: 5 minutes
measure: Timed up and go test
timeFrame: 3 minutes
measure: Sit to stand test
timeFrame: 3 minutes
measure: Countermovement jump test
timeFrame: 3 minutes
measure: Sahrmann five-level core stability test
timeFrame: 5 minutes
measure: Rotatory stability test
timeFrame: 3 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Shing-Tian, Chiang
Study officials:
References: